Skip to main content

Advertisement

SpringerLink
Log in

Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist’s perspective

  • REVIEW ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Appendiceal mucinous lesions’ classification and nomenclature has been modified several times along the last decades, reflecting their great heterogeneity and making difficult to compare results and draw conclusions. Despite its nearby origin, appendiceal mucinous lesions have a distinctive behaviour compared to colorectal cancer, including their molecular and genetic markers. Due to their low frequency, their management is not well standardised. However, surgery is considered the cornerstone of treatment. Their indolent behaviour has encouraged surgeons to apply more aggressive treatments, such as cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), that may extend overall survival. Chemotherapy is reserved for unresectable and/or disseminated disease and could play a role in the adjuvant and neoadjuvant setting. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is recently emerging as a possible alternative for treatment in advanced disease although its results in long-term survival are lacking Hereby, we review the available evidence in the management of appendiceal mucinous lesions, including localised and disseminated disease, with a special emphasis on the oncological perspective, focusing on the lights and shadows of the systemic treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Choudry HA, Pai RK. Management of mucinous appendiceal tumors. Ann Surg Oncol. 2018;25(8):2135–44.

    Article  PubMed  Google Scholar 

  2. Turaga KK, Pappas SG, Gamblin TC. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19(5):1379–85.

    Article  PubMed  Google Scholar 

  3. Carmignani CP, Hampton R, Sugarbaker CE, Chang D, Sugarbaker PH. Utility of CEA and CA 19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87(4):162–6.

    Article  PubMed  Google Scholar 

  4. Wang H, Chen YQ, Wei R, Wang QB, Song B, Wang CY, et al. Appendiceal mucocele: a diagnostic dilemma in differentiating malignant from benign lesions with TC. Am J Roentgenol. 2013;201(4):590–5.

    Article  Google Scholar 

  5. Schuitevoerder D, Plana A, Izquierdo FJ, Votanopoulos KI, Cusack JC, Bijelic L, et al. The Chicago Consensus on Peritoneal Surface Malignancies: management of appendiceal neoplasms. Ann Surg Oncol. 2020;27(6):1753–60.

    Article  Google Scholar 

  6. Menassel B, Duclos A, Passot G, Dohan A, Payet C, Isaac S, et al. Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. Eur J Surg Oncol. 2016;42(4):558–66.

    Article  CAS  PubMed  Google Scholar 

  7. Glasgow SC, Gaertner MDW, Stewart MDD, Davids J, Alavi MDK, Paquette MDIM, et al. The American Society of Colon and Rectal, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. Dis Colon Rectum. 2019;62(12):1425–38.

    Article  PubMed  Google Scholar 

  8. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.

    Article  PubMed  Google Scholar 

  9. Overman MJ, Kakar S, Carr NJ, Hanna NN, Holowatyj AN, Washington MK, Goldberg RM. AJCC Cancer Staging System: Appendix. Version 9. 9th ed. Chicago: American College of Surgeons; 2022.

    Google Scholar 

  10. Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, Zureikat AH, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: Identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014;27(11):1521–39.

    Article  PubMed  Google Scholar 

  11. Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C, Memis B, et al. Appendiceal mucinous neoplasms: diagnosis and management. Oncologist. 2018;23(1):137–137.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013;18:1270–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol. 2002;15(6):599–605.

    Article  PubMed  Google Scholar 

  14. Stein A, Strong E, Gamblin TC, Clarke C, Tsai S, Thomas J, et al. Molecular and genetic markers in appendiceal mucinous tumors: a systematic review. Ann Surg Oncol. 2020;27(1):85–97.

    Article  PubMed  Google Scholar 

  15. Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol. 2016;27(11):2097–103.

    Article  CAS  PubMed  Google Scholar 

  16. Foote MB, Walch H, Chatila W, Vakiani E, Chandler C, Steinruecke F, et al. Molecular classification of appendiceal adenocarcinoma. J Clin Oncol. 2023;41(8):1553–64.

    Article  CAS  PubMed  Google Scholar 

  17. Matias-García B, Mendoza-Moreno F, Blasco-Martínez A, Busteros-Moraza JI, Diez-Alonso M, Garcia-Moreno NF. A retrospective analysis and literature review of neoplastic appendiceal mucinous lesions. BMC Surg. 2021;21(1):1–7.

    Article  Google Scholar 

  18. Barrios P, Losa F, Gonzalez-Moreno S, Rojo A, Gómez-Portilla A, Bretcha-Boix P, et al. Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei). Clin Transl Oncol. 2016;18(5):437–48.

    Article  CAS  PubMed  Google Scholar 

  19. Pai RK, Hartman DJ, Gonzalo DH, Lai KK, Downs-Kelly E, Goldblum JR, et al. Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. Hum Pathol. 2014;45(2):227–35.

    Article  CAS  PubMed  Google Scholar 

  20. Li F, Lu Y, Hou F, Ma R, Wang D, Qi C. Significance of the entire appendiceal evaluation in the diagnosis of serrated lesions, low-grade appendiceal mucinous neoplasm, and appendiceal diverticulosis disease. Front Oncol. 2022;11:1–10.

    Article  Google Scholar 

  21. Hoehn RS, Rieser CJ, Choudry MH, Melnitchouk N, Hechtman J, Bahary N. Current management of appendiceal neoplasms. Am Soc Clin Oncol Educ B. 2021;41:118–32.

    Article  Google Scholar 

  22. Arnason T, Kamionek M, Yang M, Yantiss RK, Misdraji J. Significance of proximal margin involvement in low-grade appendiceal mucinous neoplasms. Arch Pathol Lab Med. 2015;139(4):518–21.

    Article  CAS  PubMed  Google Scholar 

  23. González-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91(3):304–11.

    Article  PubMed  Google Scholar 

  24. Baumgartner JM, Srivastava A, Melnitchouk N, Drage MG, Huber AR, Gonzalez RS, et al. A multi-institutional study of peritoneal recurrence following resection of low-grade appendiceal mucinous neoplasms. Ann Surg Oncol. 2021;28(8):4685–94.

    Article  PubMed  Google Scholar 

  25. Roxburgh CS, Fenig YM, Cercek A, Shia J, Rassam RM, Paty PB, et al. Outcomes of low-grade appendiceal mucinous neoplasms with remote acellular mucinous peritoneal deposits. Ann Surg Oncol. 2019;26(1):118–24.

    Article  PubMed  Google Scholar 

  26. Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33(2):248–55.

    Article  PubMed  Google Scholar 

  27. Honoré C, Caruso F, Dartigues P, Benhaim L, Chirica M, Goéré D, et al. Strategies for preventing pseudomyxoma peritonei after resection of a mucinous neoplasm of the appendix. Anticancer Res. 2015;35(9):4943–8.

    PubMed  Google Scholar 

  28. Reiter S, Rog CJ, Alassas M, Ong E. Progression to pseudomyxoma peritonei in patients with low grade appendiceal mucinous neoplasms discovered at time of appendectomy. Am J Surg. 2022;223(6):1183–6.

    Article  PubMed  Google Scholar 

  29. Foster JM, Sleightholm RL, Wahlmeier S, Loggie B, Sharma P, Patel A. Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. World J Surg Oncol. 2016;14(1):1–7.

    Article  Google Scholar 

  30. Govaerts K, Lurvink RJ, De Hingh IHJT, Van Der Speeten K, Villeneuve L, Kusamura S, et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI / EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47:11–35.

    Article  CAS  PubMed  Google Scholar 

  31. Turaga KK, Pappas S, Gamblin TC. Right hemicolectomy for mucinous adenocarcinoma of the appendix: just right or too much? Ann Surg Oncol. 2013;20(4):1063–7.

    Article  PubMed  Google Scholar 

  32. Nasseri YY, Zhu R, Sutanto C, Wai C, Cohen JS, Ellenhorn J, et al. Role of right hemicolectomy in patients with low-grade appendiceal mucinous adenocarcinoma. Am J Surg. 2019;218(6):1239–43.

    Article  PubMed  Google Scholar 

  33. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–82.

    Article  PubMed  Google Scholar 

  34. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6(8):727–31.

    Article  CAS  PubMed  Google Scholar 

  36. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Baratti D, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.

    Article  PubMed  Google Scholar 

  37. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, et al. A multi-center randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434–43.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–70.

    Article  PubMed  Google Scholar 

  39. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.

    Article  PubMed  Google Scholar 

  40. Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147–54.

    Article  PubMed  Google Scholar 

  41. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.

    Article  PubMed  Google Scholar 

  42. Byrne RM, Gilbert EW, Dewey EN, Herzig DO, Lu KC, Billingsley KG, et al. Who undergoes cytoreductive surgery and perioperative intraperitoneal chemotherapy for appendiceal cancer? An analysis of the National Cancer Database. J Surg Res. 2019;238:198–206.

    Article  PubMed  Google Scholar 

  43. Baratti D, Kusamura S, Guaglio M, Milione M, Pietrantonio F, Cavalleri T, et al. Relapse of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: pattern of failure clinical management and outcomes. Ann Surg Oncol. 2023;30(1):404–14.

    Article  PubMed  Google Scholar 

  44. Milovanov V, Sardi A, Aydin N, Nieroda C, Sittig M, Nunez M, et al. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin. Eur J Surg Oncol. 2015;41(7):881–5.

    Article  CAS  PubMed  Google Scholar 

  45. Almasri SS, Paniccia A, Hammad AY, Pai RK, Bahary N, Zureikat AH, et al. The role of adjuvant chemotherapy following right hemicolectomy for non-metastatic mucinous and nonmucinous appendiceal adenocarcinoma. J Gastrointest Surg. 2022;26:171–80.

    Article  PubMed  Google Scholar 

  46. Asare EA, Compton CC, Hanna NN, Kosinski LA. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;33(3):213–21.

    Article  Google Scholar 

  47. Kolla BC, Ganesan C, Petersen A, Chengappa M, Gaertner WB, Blaes A. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med. 2020;9:3400–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Baron E, Sardi A, Caitlin M, Nikiforchin A, Lopez-Ramirez F, Nieroda C, et al. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2023;49(1):179–87.

    Article  PubMed  Google Scholar 

  49. Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KIMR, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109:740–5.

    Article  PubMed  Google Scholar 

  50. Sugarbaker PH, Bijelic L, Chang D, Yoo DAL. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576–81.

    Article  PubMed  Google Scholar 

  51. Munoz-Zuluaga CA, King MC, Ledakis P, Gushchin V, Sittig M, Nieroda C, et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS / HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. Eur J Surg Oncol. 2019;45(9):1598–606.

    Article  PubMed  Google Scholar 

  52. Baron E, Sardi A, King MC, Nikiforchin A, Lopez-Ramirez F, Nieroda C, et al. Systemic chemotherapy for high-grade mucinous appendiceal cancer with peritoneal spread after unsuccessful CRS / HIPEC. Ann Surg Oncol. 2022;29(11):6581–9.

    Article  PubMed  Google Scholar 

  53. Farquharson AL, Pranesh N, Witham G, Swindell R, Taylor MB, Renehan AG, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99(4):591–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pietrantonio F, Maggi C, Fanetti G, Iavocelli R, Di Bartolomeo M, Richinni F, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014;19:845–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. Cancer. 2010;116:316–22.

    Article  PubMed  Google Scholar 

  56. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol. 2015;22:2578–84.

    Article  CAS  PubMed  Google Scholar 

  57. Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, et al. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. J Transl Med. 2016;14(125):1–7.

    Google Scholar 

  58. Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77.

    Article  PubMed  Google Scholar 

  59. Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols: PIPAC practice guidelines. Eur J Surg Oncol. 2022;48(4):789–94.

    Article  PubMed  Google Scholar 

  60. Nowacki M, Alyami M, Villeneuve L, Mercier F, Hubner M, Willaert W, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol. 2018;44(7):991–6.

    Article  PubMed  Google Scholar 

  61. Raoof M, Malhotra G, Kohut A, O’Leary M, Frankel P, Tran T, et al. PIPAC for the treatment of gynecologic and gastrointestinal peritoneal metastases: technical and logistic considerations of a phase 1 trial. Ann Surg Oncol. 2022;29(1):175–85.

    Article  PubMed  Google Scholar 

  62. Graversen M, Detlefsen S, Ainsworth AP, Fristrup CW, Knudsen AO, Pfeiffer P, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study. Ann Surg Oncol. 2023;30(5):2634–44.

    Article  PubMed  Google Scholar 

  63. Kurtz F, Struller F, Horvath P, Solass W, Bösmüller H, Königsrainer A, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract. 2018;2018:2743985.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori. 2020;106(1):70–8.

    Article  PubMed  Google Scholar 

  65. Somashekhar SP, Abba J, Sgarbura O, Alyami M, Teixeira Farinha H, Rao RG, et al. Assessment of treatment response after pressurized intra-peritoneal aerosol chemotherapy (PIPAC) for appendiceal peritoneal metastases. Cancers (Basel). 2022;14(20):4998.

    Article  PubMed  Google Scholar 

  66. Gupta AR, Brajcich BC, Yang AD, Bentrem DJ, Merkow RP. Necessity of posttreatment surveillance for low-grade appendiceal mucinous neoplasms. J Surg Oncol. 2021;124(7):1115–20.

    Article  PubMed  Google Scholar 

  67. Overman MJ, Compton CC, Raghav K, Lambert LA (2022) Appendiceal mucinous lesions. UpToDate

  68. Hara K, Saito T, Hayashi T, Yimit A, Takahashi M. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathol Res Pract. 2015;211(9):657–64.

    Article  CAS  PubMed  Google Scholar 

  69. Borazanci E, Millis SZ, Kimbrough J, Doll N, Von HD, Ramesh K. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol. 2017;8(1):164–72.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Gonzalez RS, Carr NJ, Liao H, Pai RK, Agostini-Vulaj D, Misdraji J. High-grade appendiceal mucinous neoplasm. Arch Pathol Lab Med. 2022;146(12):1471–8.

    Article  CAS  PubMed  Google Scholar 

  71. Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22:1274–9.

    Article  PubMed  Google Scholar 

  72. Graversen M, Detlefsen S, Asmussen J, Mahdi B, Fristrup C, Pfeiffer P, Mortensen MB. Treatment of peritoneal carcinomatosis with Pressurized  IntraPeritoneal Aerosol Chemotherapy-PIPAC-OPC2. Pleura Peritoneum. 2018;3(2):20180108

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Thanks are due to Mark Wills, academic translator and proofreader, for his help with the style and inner coherence of the language used in this article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Servicio Oncología Médica, Hospital Universitario Valme, Ctra. de Cádiz Km 548,9, C.P.: 41014, Seville, Spain

    Carlos Ayala-de Miguel, Jerónimo Jiménez-Castro, Adrián Sánchez-Vegas, Sebastián Díaz-López & Manuel Chaves-Conde

Authors
  1. Carlos Ayala-de Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerónimo Jiménez-Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrián Sánchez-Vegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sebastián Díaz-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel Chaves-Conde
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Carlos Ayala de Miguel: investigation, writing—original draft; writing—review and editing, visualisation. Jerónimo Jiménez Castro: conceptualisation, investigation, supervision, writing—review and editing, visualisation. Adrián Sánchez Vegas: investigation, writing—review and editing. Sebastián Díaz López: investigation, writing—review and editing. Manuel Chaves Conde: conceptualisation, supervision, writing—review and editing, visualisation.

Corresponding author

Correspondence to Jerónimo Jiménez-Castro.

Ethics declarations

Conflict of interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: C. Ayala-de Miguel: Honoraria: LEO Pharma. Travel expenses/Congress Support: Pfizer, Novartis. J. Jiménez-Castro: Honoraria: Servier, Merck. Travel expenses/Congress Support: Amgen. S. Díaz-López: Travel expenses/Congress Support: Merck, Pfizer, LEO Pharma, IPSEN Pharma. M. Chaves-Conde: Honoraria: Merck. Travel expenses/Congress Support: Pfizer, MSD, Merck. A. Sánchez-Vegas: Honoraria: MSD, GSK y Pfizer. Travel expenses/Congress Support: GSK, Amgen.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of study, no informed consent is required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayala-de Miguel, C., Jiménez-Castro, J., Sánchez-Vegas, A. et al. Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist’s perspective. Clin Transl Oncol 26, 1287–1299 (2024). https://doi.org/10.1007/s12094-023-03356-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03356-6

Keywords

Search

Navigation